key: cord-0956229-inc3fskt
authors: Candoni, Anna; Callegari, Chiara; Zannier, Maria Elena; Fanin, Renato
title: Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
date: 2022-02-04
journal: Blood Adv
DOI: 10.1182/bloodadvances.2021006949
sha: 436b99a736d94a6a7a142b69bcb83e1516f9e332
doc_id: 956229
cord_uid: inc3fskt

nan

Patients with acute myeloid leukemia (AML) and myelodysplastic syndromes 15 (MDS) treated with hypomethylating agents (HMA) alone or in combination with 16 venetoclax are an extremely vulnerable population due to advanced age, 17 comorbidities and treatment induced neutropenia (1, 2) . In addition, many of these 18 patients receive HMA therapy in an outpatient setting and lasting until 19 hematological disease progression (1, 2) . All these aspects make these patients very 20 susceptible to breakthrough infection by SARS-CoV-2, especially given the 21 emergence of new, highly contagious, variants (3-5). Since blood cancer patients 22 have been excluded from vaccine clinical trials, real-world data on vaccine 23 immunogenicity are very important in this setting (6) . In particular, the asessment of 24 antibody (Ab) levels may play a role in establishing a response to vaccination in this 25 frail patient population. It is well known that the seroconversion rate after SARS- (Table 1B and 1C) . Mean and median antibody 70 titers were significantly higher after the third dose than after the second dose 71 (P=0.003 T-test; P=0.0006 Mann-Whitney U-test) but with no significant differences 72 between the two cohorts. Interestingly, as shown in Figure 1C AUTHOR CONTRIBUTIONS. Data collection and analysis was carried out by all authors. Manuscript was written by AC. Statistical analysis was performed by AC. All authors were responsible for the final approval of this paper.

American Society of Hematology 2020 guidelines for treating newly diagnosed 102 acute myeloid leukemia in older adults

Hypomethylating agents (HMA) 105 for the treatment of acute myeloid leukemia and myelodysplastic syndromes: 106 mechanisms of resistance and novel HMA-based therapies

COVID-19 infection in adult patients with hematological malignancies

European Hematology Association Survey (EPICOVIDEHA)

Clinical 115 characteristics and risk factors associated with COVID-19 severity in patients 116 with haematological malignancies in Italy: a retrospective, multicentre, cohort 117 study

Characteristics, clinical outcomes, and 121 risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: 122 experience of the PETHEMA group

Efficacy and 125 Safety of the mRNA-1273 SARS-CoV-2 Vaccine

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in 130 patients with haematological malignancies

Immunogenicity of COVID-19 vaccines in patients with hematological 135 malignancy: a systematic review and meta-analysis